Overview

  • Product name
    Anti-Ras antibody [F132-62]
    See all Ras primary antibodies
  • Description
    Mouse monoclonal [F132-62] to Ras
  • Host species
    Mouse
  • Specificity
    Reactive with the Ras translational products of the H-, K- and N-ras human, as well as mouse and rat c- and v-ras oncogenes. We have received mixed results for Western Blot.
  • Tested applications
    Suitable for: ICC/IF, IHC-Fr, IHC-P, IP, ICC, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant full length protein (Human).

  • Positive control
    • Sw480 or Y1 cells or normal skin tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab16907 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration.
IHC-Fr Use a concentration of 5 µg/ml.
IHC-P Use a concentration of 5 µg/ml.
IP Use a concentration of 4 µg/ml.
ICC Use a concentration of 2 µg/ml.
Flow Cyt Use 1µg for 106 cells.

ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.

Target

  • Function
    Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in disease
    Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similarities
    Belongs to the small GTPase superfamily. Ras family.
  • Post-translational
    modifications
    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localization
    Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links
  • Alternative names
    • C-BAS/HAS antibody
    • c-H-ras antibody
    • C-HA-RAS1 antibody
    • CTLO antibody
    • GTPase HRas antibody
    • GTPase KRas antibody
    • GTPase NRas antibody
    • H-Ras-1 antibody
    • H-RASIDX antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • HRAS antibody
    • HRAS1 antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-RAS antibody
    • KRAS antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-RAS antibody
    • N-terminally processed antibody
    • NRAS antibody
    • NRAS1 antibody
    • p21ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    • v ras neuroblastoma RAS viral oncogene homolog antibody
    see all

Images

  • Overlay histogram showing HeLa cells stained with ab16907 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab16907, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 100% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.

References

This product has been referenced in:
See all 5 Publications for this product

Customer reviews and Q&As

1-4 of 4 Abreviews or Q&A

Answer

Thank you for contacting us.

We unfortunately do not have IHC tested image for this antibody so I am sorry we are unable to provide you this data.

We do however recommend using this antibody at 5ug/ml which is however for guidelines only. I can suggest using 1/50, 100 or 1/200 dilution for optimization.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

Thank you for contacting us.
ab97488 and ab6548 are alternative to sc-520. Please note this assumption is based on the location of immunogen only. We might not have similar species or application data.
ab140962 and ab140377 are expected alternatives for sc29.
I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

Thank you for contacting us. Because we carry over 100,000 products, it isn't feasible for us to keep small sample sizes of our products.

We are happy to reassure our customers that all of our products are covered by our Abpromise, which guarantees that the product will work in the applications and species specified on the datasheet, or we will offer a replacement, credit, or refund within 6 months of purchase.

All the antibodies listed have been successfully tested in IHC-P. Furthermore, ab26 has two references for the use in IHC-P, ab16795 has one. However, if the species you want to work with is not tested, please contact me so we could discuss if we could offer you our AbTrial discount.

Nonetheless, if you should come across any problem with these antibodies, we are happy to help.

In addition, we like to encourage all of our customers to submit an Abreview via the online product datasheet. We always appreciate customer feedback, whether positive or negative, and we make all product information available to researchers. Plus, each Abreview earns Abpoints that can be used for discounts on future purchases or rewards such as Amazon.com gift certificates.

To find out more about our Abreview system, please see the following link:

https://www.abcam.com/abreviews

I hope this information is helpful. Please do not hesitate to contact us again with any other questions.

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (HeLa)
Specification
HeLa
Fixative
Paraformaldehyde
Blocking step
Serum as blocking agent for 15 minute(s) · Concentration: 10%

Abcam user community

Verified customer

Submitted Mar 30 2007

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up